Methods and Compositions of Defensin-Antigen Fusion Proteins and Chemokine-Antigen Fusion Proteins as Vaccines for Tumors and Viral Infection
Description of Invention:
This invention relates to the development of a vaccine for increasing the immunogenicity of a tumor antigen, thus useful for the treatment of cancer, as well as a vaccine for increasing the immunogenicity of a viral antigen, thus allowing treatment of viral infection. In particular, the present invention provides a fusion protein comprising a defensin or chemokine fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection. In particular, the C-C chemokine macrophage inflammatory protein (MIP-3alpha) was shown to be particularly effective in increasing the immunogenicity of a tumor antigen. Aspects of this work have been published as a PCT patent application with publication number WO 03/025002.
Inventors:
Arya Biragyn (NCI)
Patent Status:
DHHS Reference No. E-024-2002/0
Licensing Status: This technology is no longer available for licensing.
Portfolios: Infectious Diseases Cancer
Cancer -Therapeutics-Vaccines Infectious Diseases -Therapeutics-Anti-Viral Cancer -Therapeutics Infectious Diseases -Therapeutics Infectious Diseases -Vaccines
For Additional Information Please Contact: Thomas P. Clouse J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4076
Email: clousetp@mail.nih.gov
Fax: (301) 402-0220
